You are here

Recent Pfizer Press Releases

5/18/16 5:00pm EDT
Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

More than 40 accepted abstracts highlight innovation in immuno-oncology and other novel modalities across multiple tumor types

Pfizer invites public to view and listen to webcast of conference call with analysts on Wednesday, June 8 at 10 a.m. EDT to review oncology business and ASCO data presentations


Pfizer Inc. (NYSE:PFE) today announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action. Presentations include eight oral presentations and five poster discussions that span Pfizer’s internal and collaborative scientific advances.

5/17/16 8:00am EDT
Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA)

Findings Show the Importance of Patient and Physician Dialogue to Achieve Optimal Disease Management Outcomes

Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management.

5/16/16 6:45am EDT
Pfizer to Acquire Anacor

  • Strong fit with Pfizer’s Inflammation and Immunology portfolio
  • Expected to enhance near-term revenue growth for the innovative business
  • Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if approved, has the potential to be an important first-line treatment option for patients with atopic dermatitis

Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes.

5/13/16 6:30am EDT
Pfizer Presents Results from Two Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Studies at the European Society for Paediatric Infectious Diseases Meeting

Secondary Data Support That TRUMENBA® Protects Against Additional Meningococcal Serogroup B Strains

Pfizer Inc. (NYSE:PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responses against ten additional MnB strains, in both adolescents and young adults.

5/11/16 8:00am EDT
Pfizer Awards More Than $1 Million in Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

  • Metastatic Research Accounts for Only About 7 Percent of Total Breast Cancer Research Investment1
  • Awards Complement Ongoing Initiative, Which has Reached More Than 40 Million People to Date

Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering gaps in the public’s knowledge of MBC and bringing greater attention to the unique needs and experiences of people living with this disease.

5/3/16 6:45am EDT

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
4/28/16 12:00pm EDT
Pfizer Hosts Annual Meeting of Shareholders

Declares 30-Cent Second-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent second-quarter 2016 dividend on the company’s common stock, payable June 1, 2016, to shareholders of record at the close of business on May 13, 2016.

4/26/16 8:30am EDT
Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

Pfizer research program only one to assess role of PCSK9 inhibitors in reducing risk of cardiovascular events in high-risk patients without history of cardiovascular events

Pfizer Inc. today announced patient enrollment completion in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab.

4/22/16 6:30pm EDT
CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet

Authors conclude no significant increase in serious neuropsychiatric adverse events with CHANTIX/CHAMPIX relative to placebo or nicotine patch

Smokers treated with CHANTIX/CHAMPIX had significantly higher quit rates than those treated with bupropion, nicotine patch or placebo

Pfizer Inc. (NYSE:PFE) today announced results published in The Lancet from the largest clinical trial of approved smoking cessation medicines, called EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study).

4/21/16 2:00pm EDT
Pfizer Invites Public to Listen to Webcast of April 28 Annual Meeting of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 28, 2016.

4/19/16 8:00am EDT
Pfizer Announces Positive Top-Line Results for Phase 3 PALOMA-2 Clinical Trial of IBRANCE® (palbociclib)

Phase 3 Trial Provides Confirmatory Evidence for IBRANCE in the First-Line Setting and Will Support Global Regulatory Submissions

4/7/16 8:30am EDT
Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care

Experimental “Internet of Things” System Uses Connected Devices to Enable Remote Measurement of Health and Quality of Life in Real-Time

Multi-Year Project Could Potentially Change How Clinical Trials are Conducted

NEW YORK & ARMONK, N.Y.--Pfizer Inc. (NYSE:PFE) and IBM (NYSE:IBM) today announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

4/6/16 11:00am EDT
Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13®

Four-Dose Vial Will Help Address Infrastructure Challenges in Developing Countries

NEW YORK--Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.

4/6/16 6:45am EST
Pfizer Announces Termination of Proposed Combination with Allergan

NEW YORK, N.Y., April 6 - Pfizer Inc. (NYSE: PFE) today announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.

4/5/16 5:34pm EDT
FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications

NEW YORK--The United States (U.S.) Food and Drug Administration (FDA) today approved Celltrion’s INFLECTRA™ (biosimilar infliximab) across all eligible indications of the reference product, Remicade® (infliximab).1INFLECTRA is now the first and only biosimilar monoclonal antibody (mAb) therapy, and only the second biosimilar, to be approved in the U.S.

4/5/16 8:00am EDT
Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinom

  • JAVELIN Renal 101 marks first Phase III study to evaluate avelumab in combination with a small molecule tyrosine kinase inhibitor therapy
  • Combination approach leverages Pfizer’s broad oncology portfolio and heritage in renal cell carcinoma
  • First-line study evaluating avelumab in combination with INLYTA® (axitinib) compared with SUTENT® (sunitinib malate) monotherapy

DARMSTADT, Germany & NEW YORK--Merck and Pfizer (NYSE:PFE) today announced the treatment of the first patient in a Phase III study of avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal ant

4/5/16 7:00am EST
Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

NEW YORK, N.Y., April 5 – Pfizer Inc. announced today top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis triaL (OPAL) Broaden.

4/4/16 7:05pm EDT
Pfizer and Allergan Issue Statement

NEW YORK--Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today issued the following statement regarding the recently issued Department of Treasury Notice:

“We are conducting a review of the U.S. Department of Treasury’s actions announced today. Prior to completing the review, we won’t speculate on any potential impact.”

4/1/16 8:00am EDT
Pfizer Announces Positive Topline Results from Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

SPIRE-AI study evaluating bococizumab administered with pre-filled pen (autoinjector) met co-primary endpoints